Experimental Pompe Therapy Shows Early Promise in Trial
PHILADELPHIA, PA — Aro Biotherapeutics reported interim data from a Phase 1b study of ABX1100, an investigational therapy for late-onset Pompe disease, showing the drug was generally well tolerated and …
Experimental Pompe Therapy Shows Early Promise in Trial Read More